AUAUniversity

This podcast was funded by and developed in collaboration with AstraZeneca.

Learning Objectives:

At the conclusion of this activity, participants will be able to:

1. Identify approved PARP Inhibitors for prostate cancer and patients who may benefit from PARP Inhibitor‐based therapy.

2. Evaluate available clinical safety and efficacy data for PARP Inhibitors.

3. Describe indications and contraindications for PARP Inhibitors in patients with advanced prostate cancer.

4. Identify how to manage adverse events that patients may experience while taking a PARP Inhibitors.

For more information: https://auau.auanet.org/content/overview-parpi-adverse-event-management-podcast-2021

This podcast was funded by and developed in collaboration with AstraZeneca.

Learning Objectives:

At the conclusion of this activity, participants will be able to:

1. Identify the role of genomic testing in men with different stages of prostate cancer.

2. Recognize the need for collaboration with genetic counselors for optimal genetic evaluation tailored to an individual prostate cancer patient.

3. Explain the criteria for genomic testing of prostate cancer patients across the disease spectrum, current NCCN testing guidelines, difference between germline and somatic testing, different testing modalities currently available gene panels, options for testing these men, and appropriate timing for testing.

4. Interpret the results of genomic testing, implications for shared‐decision with patients based on the test results, and impact on novel therapies and personalized treatment for prostate cancer care.

5. Apply best practices and lessons learned for operationalizing testing and testing workflows in urology practices.

For more information: https://auau.auanet.org/content/genomic-testing-prostate-cancer-podcast-podcast-2021

Support provided by independent educational grants from Astellas, Bayer HealthCare Pharmaceuticals Inc., Genentech, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., Merck and Pfizer, Inc.

CME Available: https://auau.auanet.org/node/31815

At the conclusion of this educational series, participants will be able to:

1. Discuss the impact of SDM on patients and on patient-clinician communication.

2. Identify at least one implementation strategy for using SDM in clinical practice.

3. Apply SDM techniques in a role-playing exercise with other colleagues.

4. Incorporate culturally sensitive communications to ensure quality SDM and reduce biases.

5. Utilize the knowledge and experience they have gained through role-play into their routine practice-counseling patients.

This educational series is supported by independent educational grants from Olympus Corporation of the Americas and Teleflex.

CME Available: https://auau.auanet.org/node/32295

At the conclusion of this activity, participants will be able to:

1. Describe the role of the AUA Clinical Guidelines for the Surgical Management BPH.

2. Discuss the evidence base for current technologies, including pivotal studies, and be able to define the role and clinical expectation for each of them.

3. Interpret the current clinical results and compare the patient experiences of these treatments in relation to more established and even abandoned treatments for patient groups with similar characteristics.

Designed to encourage high quality, evidence-based testing and care of patients with bladder cancer, this podcast episode focuses on Genetic Testing for Bladder Cancer. Listen today to discover the differences between molecular markers and genetic testing, how genetic testing for bladder cancer is performed and current considerations of genetic findings.

Co-Host: Neal Shore, MD, FACS

Acknowledgement:

This podcast was funded by Janssen Oncology.

For more information: https://auau.auanet.org/content/genetic-testing-bladder-cancer-podcast-2021

Contemporary Pharmacotherapy for OAB 2021: Monotherapy and Combined Pharmacotherapy to Optimize Treatment (2021)

CME Available: https://auau.auanet.org/node/31460

ACKNOWLEDGEMENTS

Support provided by independent educational grants from AbbVie, Astellas, Medtronic, Urovant Sciences, Inc.

At the conclusion of the activity, participants will be able to:

1. Define the similarities and differences between the various oral pharmacotherapies for overactive bladder (OAB).

2. Review the principles of physiology and pharmacotherapy for currently available agents, including the anti-muscarinics and beta-3 agonists and combination therapy.

3. Express the importance of setting proper patient expectations regarding treatment of OAB and the potential need for sequential and even additive therapies.

4. Analyze the clinical (and theoretical) advantages and limitations of currently available agents.

5. Discuss potential future pharmacological pathways and therapies for OAB.

Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider (2021)

CME Available: https://auau.auanet.org/node/31450

ACKNOWLEDGEMENTS

Support provided by independent educational grants from Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Merck, Pfizer, Inc. and Sanofi Genzyme.

At the conclusion of the activity, participants will be able to:

1. Explain the mechanism of checkpoint inhibitors.

2. Describe historical and novel treatments for systemic prostate cancer, including their mechanism, efficacy, side effects, and where they fit in the disease map.

3. Describe historical and novel treatments for systemic bladder cancer, including their mechanism, efficacy, side effects, and where they fit in the disease map.

4. Describe historical and novel treatments for systemic kidney cancer, including their mechanism, efficacy, side effects, and where they fit in the disease map.

Trimodality Therapy for Management of Muscle Invasive Bladder Cancer (2021)

CME Available: https://auau.auanet.org/node/31470

ACKNOWLEDGEMENTS

Support provided by independent educational grants from AstraZeneca, Bristol Myers Squibb and Merck.

At the conclusion of the activity, participants will be able to:

1. Demonstrate an understanding of prospective randomized trials and large institutional experiences in tri-modality therapy for muscularis propria invasive bladder cancer.

2. Identify which patients are candidates for tri-modal bladder sparing therapy, and which patients are not candidates and should instead undergo radical cystectomy.

3. Explain the technique and importance of aggressive initial transurethral resection, repeat transurethral resection and ongoing cystoscopic surveillance of the bladder.

4. Outline the coordinated multidisciplinary technique in tri-modality therapy, including radio-sensitizing chemotherapy agents, radiation fields, and adjuvant chemotherapy.

5. Describe the indications for salvage cystectomy, discuss management of noninvasive recurrences, and understand the quality of life and potential toxicities after tri-modal therapy.

Diagnosis and Management of Localized, Locally Advanced and Advanced Kidney Cancer (2021)

CME Available: https://auau.auanet.org/node/31465

ACKNOWLEDGEMENTS

Support provided by independent educational grants from AstraZeneca, Bristol Myers Squibb and Merck.

At the conclusion of the activity, participants will be able to:

1. Differentiate among the subtypes of kidney cancer, with emphasis on clinical management decisions and outline ways in which knowledge of kidney cancer subtypes can alter surgical approach.

2. Apply advanced strategies for partial nephrectomy for patients with endophytic, hilar and multiple tumors including role of warm ischemia, intraoperative ultrasound, techniques for hemostatic control, the role of off-clamp and selective hilar clamping, the use of the retroperitoneal approach, and methods for renorrhaphy.

3. Employ techniques for management of large and/or locally advanced tumors including management of renal vein or inferior vena cava invasion and the use of lymphadenectomy.

4. Identify the role of cytoreductive nephrectomy and/or resection of metastatic foci in patients with advanced disease.

5. Describe new and emerging targeted therapy and immuno-oncology options for patients with locally-advanced and advanced kidney cancer and the role of adjuvant therapy.

Incorporating Genomic Testing For Prostate Cancer into Your Practice (2021)

CME Available: https://auau.auanet.org/node/31455

ACKNOWLEDGEMENTS

Support provided by independent educational grants from Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Merck, Pfizer, Inc. and Sanofi Genzyme.

At the conclusion of the activity, participants will be able to:

1. Describe the seminal validation studies for prostate cancer genomic testing.

2. List the different prognostic endpoints provided by various genomic tests.

3. Identify appropriate genomic testing based on a patient's unique clinical characteristics.

4. Review the AUA and NCCN guidelines for genomic testing for prostate cancer.